Systemic reactions generally mild, slightly more likely among those receiving both vaccines compared with COVID-19 mRNA booster alone<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, July 21, 2022 (HealthDay News) — Simultaneous administration of COVID-19 mRNA booster and influenza vaccines may increase the likelihood of systemic reactions, according to a study published online July 15 in JAMA Network Open<\/em>.<\/p>\n Anne M. Hause, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues evaluated adverse events and health impacts associated with simultaneously administering COVID-19 mRNA booster and seasonal influenza vaccines in the U.S. population. Self-reported vaccine data from 92,023 individuals aged 12 years and older were collected on days 0 to 7 after vaccination between Sept. 22, 2021, and May 1, 2022, through v-safe, a voluntary smartphone-based monitoring system.<\/p>\n The researchers found that in the week following vaccination, any systemic reactions were reported by 58.9 percent of 61,390 respondents who simultaneously received the Pfizer-BioNTech booster and influenza vaccines and 68.6 percent of 30,633 respondents who simultaneously received the Moderna booster and influenza vaccines. Compared with respondents who received only a COVID-19 mRNA vaccine booster, those who simultaneously received influenza and Pfizer-BioNTech booster vaccines or influenza and Moderna booster vaccines were slightly more likely to report any systemic reaction in the week following simultaneous vaccination, although most reactions were mild.<\/p>\n These results may help better characterize the outcomes associated with simultaneously administered COVID-19 booster and influenza vaccines in the U.S. population, the authors write.<\/p>\n Abstract\/Full Text<\/a><\/p>\n